

08-15-03

1623



PHA 4298 (3167/9Z)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
AUG 19 2003  
TECH CENTER 1600/2900

Application of John P. McKearn et al.  
Serial No. 09/868,437  
Filed June 14, 2001  
Art Unit Unknown

Confirmation No. Unknown

For USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN  
ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF  
NEOPLASIA

August 14, 2003

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

Please note that Applicants make no representation as to the accuracy or completeness of the translations of the abstracts submitted herewith.

In preparation of this Information Disclosure Statement, Applicants determined that approximately 1,131 references were cited in the application. In an effort to reduce the burden on the Office, each reference was briefly reviewed by an attorney. This review eliminated any reference that was determined to be irrelevant or merely cumulative. If the Office would like a copy

08/18/2003 MRLANCO 00000011 09868437

01 FC:1806

180.00 OP

of the eliminated references, they can be provided at the Office's request.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR \$1.17(p) for submission of this Information Disclosure Statement. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

\* Also enclosed is Applicants' executed Power of Attorney.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KJD/msc  
\*Enclosures

Express Mail Label No. EV 327052153 US - Box 1 of 4  
Express Mail Label No. EV 327052177 US - Box 2 of 4  
Express Mail Label No. EV 327052185 US - Box 3 of 4  
Express Mail Label No. EV 327052194 US - Box 4 of 4



**FEE TRANSMITTAL**

**RECEIVED**  
AUG 19 2003  
TECH CENTER 1600/2900

Application Number 09/868,437  
Filing Date June 14, 2001  
Confirmation No. Unknown  
Inventor(s) John P. McKearn et al.  
Attorney Docket Number PHA 4298(3167/9Z)


**METHOD OF PAYMENT**

1. ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- ☐ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- ☐ Applicant claims small entity status.
- \* 2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

**FEE CALCULATION**

1. ☐ BASIC FILING FEE Subtotal (1) \$ \_\_\_\_\_  
(Type: \_\_\_\_\_)
2. ☐ EXTRA CLAIM FEES Subtotal (2) \$ \_\_\_\_\_  
Total Claims \_\_\_\_\_  
Independent Claims \_\_\_\_\_  
Multiple Dependent Claims \_\_\_\_\_
3. ☒ ADDITIONAL FEES Subtotal (3) \$ 180.00
- ☐ Surcharge - late filing fee or oath  
☐ Surcharge - late provisional filing fee or cover sheet  
☐ Extension for reply within \_\_\_\_\_ month  
☐ Notice of Appeal  
☐ Filing a Brief in Support of an appeal  
☐ Request for ex parte Reexamination  
☐ Petitions to the Commissioner  
☒ Submission of Information Disclosure Statement  
☐ Recording each patent assignment per property  
☐ Request for Continued Examination  
☐ Other: \_\_\_\_\_

**TOTAL AMOUNT OF PAYMENT** \$ 180.00

  
Kathryn J. Doty, Reg. No. 40,593 August 14, 2003  
Date

KJD/msc


\*Enclosure

Express Mail Label No. EV 327052153 US - Box 1 of 4  
Express Mail Label No. EV 327052177 US - Box 2 of 4  
Express Mail Label No. EV 327052185 US - Box 3 of 4  
Express Mail Label No. EV 327052194 US - Box 4 of 4

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

Sheet

1

of

15

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1.	4,100,274		Dutta et al.	07-11-1978
	2.	4,105,681		Bollag et al.	08-08-1978
	3.	4,140,707		Cleare et al.	02-20-1979
	4.	4,215,215		Bollag et al.	07-29-1980
	5.	5,250,683		Holton et al.	10-05-1993
	6.	5,254,703		Holton	10-19-1993
	7.	5,272,171		Ueda et al.	12-21-1993
	8.	5,319,112		Kingston et al.	06-07-1994
	9.	5,344,991		Reitz et al.	09-06-1994
	10.	5,455,270		Kaplan et al.	10-03-1995
	11.	5,633,016		Johnson	05-27-1997
	12.	5,672,583		Chapman et al.	09-30-1997
	13.	5,686,419		Powers et al.	11-11-1997
	14.	5,696,131		Baguley et al.	12-09-1997
	15.	5,733,909		Black et al.	03-31-1998
	16.	5,767,142		LaVoie et al.	06-16-1998

Examiner  
SignatureDate  
Considered


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Complete if Known

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

Sheet

2

of

15

17.	5,824,699	Kreft et al.	10-20-1998
18.	5,837,696	Golub et al.	11-17-1998
19.	5,869,524	Failli	02-09-1999
20.	5,952,381	Chen et al.	09-14-1999

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
.	21.	DE	195 48 798	A1	Dr. Karl Thomae GmbH	07-03-1997	A
.	22.	DE	196 13 933	A1	Merck Patent GmbH	10-09-1997	A
.	23.	DE	196 26 701	A1	Hoechst AG	01-08-1998	A
.	24.	EP	0 010 458	A1	ANVAR	04-30-1980	A
.	25.	EP	0 054 168	A1	Klinge Pharma GmbH & Co.	06-23-1982	A
.	26.	EP	0 095 875	A2	Farmos Group Ltd.	12-07-1983	
.	27.	EP	0 165 904	A2	Ciba-Geigy AG	12-27-1985	A
.	28.	EP	0 199 636	A1	C.I.R.D.	10-29-1986	A
.	29.	EP	0 236 940	B1	Ciba-Geigy AG	09-16-1987	
.	30.	EP	0 260 744	B1	Janssen Pharmaceutica N.V.	03-23-1988	
.	31.	EP	0 299 402	A2	ASTA Pharma Aktiengesellschaft	01-18-1989	A
.	32.	EP	0 331 983	A2	F. Hoffmann-La Roche AG	09-13-1989	A

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

3

of

15



RECEIVED  
AUG 14 2003  
TECH CENTER 1600/2000

33.	EP	0 402 232	A1	Rhone-Poulenc Sante	12-12-1990	A
34.	EP	0 532 156	A1	Matsuno et al.	03-17-1993	
35.	EP	0 579 915	A1	F. Hoffmann-La Roche AG	01-26-1994	A
36.	EP	0 640 594	A1	Fujirebio Inc.	03-01-1995	
37.	EP	0 702 962	A2	Eli Lilly and Company	03-27-1996	
38.	EP	0 703 239	A1	Hoechst Aktiengesellschaft	03-27-1996	A
39.	EP	0 716 086	A1	Boehringer Mannheim GMBH	06-12-1996	
40.	EP	0 743 070	A2	Trnka Mudr et al.	11-20-1996	A
41.	EP	0 758 649	A1	Kureha Chemical Industry Co., Ltd.	02-19-1997	
42.	EP	0 818 443	A2	American Cyanamid Company	01-14-1998	
43.	EP	0 921 119	A1	ADIR Et Compagnie	06-09-1999	A
44.	GB	2 282 598	A	Merck & Co., Inc.	04-12-1995	
45.	WO	87/07609	A1	Taiho Pharmaceutical Co., Ltd.	12-17-1987	A
46.	WO	93/00427	A2	Erziehungsdirektion of the Canton Zurich	01-07-1993	
47.	WO	93/11145	A1	Banyu Pharmaceutical Co., Ltd.	06-10-1993	
48.	WO	93/18652	A1	Merck & Co.	09-30-1993	
49.	WO	93/20229	A1	Genentech, Inc.	10-14-1993	
50.	WO	94/02466	A1	The Du Pont Merck Pharmaceutical Company	02-03-1994	
51.	WO	94/12169	A1	Merck & Co., Inc.	06-09-1994	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/868,437  
 Filing Date June 14, 2001  
 Confirmation Number Unknown  
 First Named Inventor John P. McKearn et al.  
 Group Art Unit Unknown  
 Examiner Name Unknown

(use as many sheets as necessary)



Sheet 4 of 15 Attorney Docket No. PHA 4298 (3167/9Z)

52.	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994
53.	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994
54.	WO	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994
55.	WO	94/25431	A1	The Wellcome Foundation Limited	11-10-1994
56.	WO	94/25466	A1	Glaxo, Inc.	11-10-1994
57.	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
58.	WO	94/27980	A1	G.D. Searle & Co.	12-08-1994
59.	WO	95/02603	A2	Pharmacia S.P.A.	01-26-1995
60.	WO	95/08327	A1	The Government of the United States of America	03-30-1995
61.	WO	95/11883	A1	G.D. Searle & Co.	05-04-1995
62.	WO	95/12606	A1	The Wellcome Foundation Limited	05-11-1995
63.	WO	95/13289	A1	Chiroscience Limited	05-18-1995
64.	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995
65.	WO	95/24199	A2	Cell Therapeutics, Inc.	09-14-1995
66.	WO	95/28426	A2	La Jolla Cancer Research Foundation	10-26-1995
67.	WO	95/29892	A1	The Du Pont Merck Pharmaceutical Company	11-09-1995
68.	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
69.	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
70.	WO	96/00214	A1	Ciba-Geigy AG	01-04-1996

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/868,437
Filing Date	June 14, 2003
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 5 of 15 Attorney Docket No. PHA 4298 (3167/9Z)

71.	WO	96/00574	A1	Smithkline Beecham Corporation	01-11-1996
72.	WO	96/00581	A1	Texas Biotechnology Corporation	01-11-1996
73.	WO	96/01653	A1	Board of Regents, The University of Texas System et al.	01-25-1996
74.	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996
75.	WO	96/03392	A1	G.D. Searle & Co.	02-08-1996
76.	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996
77.	WO	96/14745	A1	The Regents of the University of California	05-23-1996
78.	WO	96/15096	A1	Bayer Corporation	05-23-1996
79.	WO	96/21667	A1	Merck Frosst Canada Inc.	07-18-1996
80.	WO	96/23791	A1	Syntex Inc.	08-08-1996
81.	WO	96/27583	A1	Pfizer Inc.	09-12-1996
82.	WO	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996
83.	WO	96/35774	A2	The Children's Medical Center Corporation	11-14-1996
84.	WO	96/36335	A1	Pharmacia S.P.A.	11-21-1996
85.	WO	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996
86.	WO	96/36622	A1	Indena S.P.A.	11-21-1996
87.	WO	96/36623	A1	Merck Frosst Canada Inc.	11-21-1996
88.	WO	96/37469	A1	Merck Frosst Canada Inc.	11-28-1996

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.


SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

Sheet

6

of

15

89.	WO	97/08145	A1	G.D. Searle & Co.	03-06-1997	
90.	WO	97/11693	A1	3-Dimensional Pharmaceuticals, Inc.	04-03-1997	
91.	WO	97/11718	A1	The Victoria University of Manchester	04-03-1997	
92.	WO	97/15666	A1	The Children's Medical Center Corporation	05-01-1997	
93.	WO	97/15676	A2	Abbott Laboratories	05-01-1997	
94.	WO	97/19068	A1	Warner-Lambert Company	05-29-1997	
95.	WO	97/19954	A1	Asta Medica Aktiengesellschaft	06-05-1997	
96.	WO	97/20835	A1	Harbor Branch Oceanographic Institution, Inc.	06-12-1997	
97.	WO	97/23451	A1	Merck Patent Gesellschaft Mit Beschränkter Haftung	07-03-1997	A
98.	WO	97/23459	A1	Warner-Lambert Company	07-03-1997	
99.	WO	97/23480	A1	The Du Pont Merck Pharmaceutical Company	07-03-1997	
100.	WO	97/24116	A2	Allergan	07-10-1997	
101.	WO	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997	
102.	WO	97/31936	A2	Wisconsin Alumni Research Foundation	09-04-1997	
103.	WO	97/33887	A1	The Du Pont Merck Pharmaceutical Company	09-18-1997	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

RECEIVED  
AUG 19 2003  
TECH CENTER 1600/2980

104.	WO	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997
105.	WO	97/36497	A2	Mars, Incorporated	10-09-1997
106.	WO	97/36860	A1	G.D. Searle & Co.	10-09-1997
107.	WO	97/36863	A1	Merck Frosst Canada Inc.	10-09-1997
108.	WO	97/37658	A1	Boehringer Mannheim Italia S.P.A.	10-16-1997
109.	WO	97/41844	A1	Alcon Laboratories, Inc.	11-13-1997
110.	WO	97/44315	A1	Warner-Lambert Company	11-27-1997
111.	WO	97/47296	A2	Mount Sinai Hospital Corporation	12-18-1997
112.	WO	97/47599	A1	Fujisawa Pharmaceutical Co., Ltd.	12-18-1997
113.	WO	97/49704	A1	Janssen Pharmaceutica N.V.	12-31-1997
114.	WO	98/03166	A1	Monsanto Company	01-29-1998
115.	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998
116.	WO	98/05635	A1	Chiroscience Limited	02-12-1998
117.	WO	98/07432	A1	American Home Products Corporation	02-26-1998
118.	WO	98/07433	A1	Bristol-Myers Squibb Company	02-26-1998
119.	WO	98/08814	A1	The Procter & Gamble Company	03-05-1998
120.	WO	98/08850	A1	The Procter & Gamble Company	03-05-1998
121.	WO	98/12181	A1	Rutgers, The State University of New Jersey	03-26-1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/868,434
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet	8	of	15	Attorney Docket No.	PHA 4298 (3167/9Z)
-------	---	----	----	---------------------	--------------------

122.	WO	98/13350	A1	Zeneca Limited	04-02-1998
123.	WO	98/14188	A1	Ilex Oncology Inc.	04-09-1998
124.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998
125.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998
126.	WO	98/25603	A1	Ilex Oncology, Inc.	06-18-1998
127.	WO	98/25896	A1	G.D. Searle & Co.	06-18-1998
128.	WO	98/27069	A1	Fujisawa Pharmaceutical Co., Ltd.	06-25-1998
129.	WO	98/33788	A1	Pharmacia & Upjohn S.P.A.	08-06-1998
130.	WO	98/40104	A2	Yale University et al.	09-17-1998
131.	WO	98/45294	A1	Astra Pharmaceuticals Ltd.	10-15-1998
132.	WO	99/01131	A1	Smithkline Beecham Corporation	01-14-1999
133.	WO	99/05104	A1	Pfizer Pharmaceuticals Inc.	02-04-1999
134.	WO	99/10331	A1	Abbott Laboratories	03-04-1999
135.	WO	99/12930	A1	Glaxo Group Limited	03-18-1999
136.	WO	99/14194	A1	Merck Frosst Canada Inc.	03-25-1999
137.	WO	99/14205	A1	Almirall Prodesfarma S.A.	03-25-1999
138.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999
139.	WO	99/23087	A1	Merck Frosst Canada & Co.	05-14-1999
140.	WO	99/31067	A1	Rutgers, The State University of New Jersey	06-24-1999

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/868,437
		Filing Date	June 14, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 9 of 15	Attorney Docket No.	PHA 4298 (3167/9Z)	

141.	WO	99/41241	A1	Rutgers, The State University of New Jersey	08-19-1999
------	----	----------	----	---	------------

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	142.	BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumouri, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1)	
	143.	BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD	
	144.	BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569	
	145.	BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11	
	146.	BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79	
	147.	BROWN, F.K., et al., Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2' Residues, J. Med. Chem., 1994, pp. 674-688, Vol. 37	
	148.	CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46	
	149.	CHERNEY, R.J., et al., Macrocyclic Amino Carboxylates as Selective MMP-8 Inhibitors, J. Med. Chem., 1998, pp. 1749-1751, Vol. 41	
	150.	DENIS, L.J., et al., Matrix metalloproteinase inhibitors: Present achievements and future prospects, Investigational New Drugs, 1997, pp. 175-185, Vol. 15	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Compleat if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/868,437
		Filing Date	June 14, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 10 of 15	Attorney Docket No.	PHA 4298 (3167/9Z)	

151.	DONG, Z, et al., Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88
152.	DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)
153.	DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41
154.	FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16
155.	FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3
156.	FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39
157.	GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54
158.	GEARING, A.J.H., et al., Processing of tumour necrosis factor- $\alpha$ precursor by metalloproteinases, Letters to Nature, Aug. 18, 1994, pp. 555-557, Vol. 370
159.	GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6
160.	GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from interferon $\alpha$ , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1198-1205, Vol. 91
161.	HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/868,437
		Filing Date	June 14, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearney et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 11 of 15	Attorney Docket No.	PHA 4298 (3167/9Z)	

162.	IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54	
163.	International Search Report for Application No. PCT/US99/30700, dated April 20, 2000	
164.	JACOBSON, I.C., et al., Structure-Based Design and Synthesis of a Series of Hydroxamic Acids with a Quaternary-Hydroxy Group in P1 as Inhibitors of Matrix Metalloproteinases, Bio-Organic & Medicinal Chemistry Letters, 1998, pp. 837-842, Vol. 8	
165.	JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3)	
166.	JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-236, Vol.11	
167.	KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3	
168.	LARK, M.W., et al., <i>In Vivo</i> Activity of Human Recombinant Tissue Inhibitor of Metalloproteinases (TIMP), Biochem Pharmacol, 1990, pp. 2041-2049, Vol. 39, No. 12	
169.	LINGEN, M.W., et al., Retinoic Acid and Interferon $\alpha$ Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58	
170.	LODE, H.N., et al., Synergy between an antiangiogenic integrin $\alpha$ , antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA., Feb. 1999, pp. 1591-1596, Vol. 96	
171.	LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
172.	MACKEAN, M.J., et al., A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12)	
173.	MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/868,437
Filing Date	June 14, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket No.	PHA 4298 (3167/9Z)

Sheet 12 of 15

12

of

15

174.	MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J. Invest. Dermatol., April 1997, Abstract 202, Vol. 108, No. 4
175.	McGEEHAN, G.M., et al., Regulation of tumor necrosis factor- $\alpha$ processing by a metalloproteinase inhibitor, Letters to Nature, Aug. 18, 1994, pp. 558-561, Vol. 370
176.	MONTGOMERY, A.M.P., et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8856-8860, Vol. 91
177.	MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1346, Vol. 39
178.	MORIMOTO, Y., et al., KB-R7785, A Novel Matrix Metalloproteinase Inhibitor, Exerts Its Antidiabetic Effect By Inhibiting Tumor Necrosis Factor- $\alpha$ Production, Life Sciences, 1997, pp. 795-803, Vol. 61, No. 8
179.	MÜLLER, H., Antio-genesis-inhibition and intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8
180.	NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58
181.	NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39
182.	O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88
183.	OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxorubicin and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 56
184.	PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha_{IIb}\beta_3$ , $\alpha_V\beta_3$ , and $\alpha_5\beta_1$ Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/868,437
		Filing Date	June 14, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 13 of 15	Attorney Docket No.	PHA 4298 (3167/9Z)	



RECEIVED  
 AUG 19 2003  
 TECH CENTER 1600/2900

185.	POWLES, T.J., II.1 Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain	
186.	PRATT, L.M., et al., Bioorganic Medicinal Chemistry Letters, 1998, pp. 1359-1364, Vol. 8	
187.	RASMUSSEN, H.S., et al., Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat, Pharmacol. Ther., 1997, pp. 69-75, Vol. 75, No. 1	
188.	RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8	
189.	ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 968-975, Vol. 17, No. 3	
190.	RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7	
191.	SCHACHTER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3	
192.	SEFTOR, R.E.B., et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89	
193.	SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, Annals of the New York Academy of Science, June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
194.	SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number 09/868,437

Filing Date June 14, 2001


Confirmation Number Unknown

First Named Inventor John P. McKearn et al.

Group Art Unit Unknown

Examiner Name Unknown

Use as many sheets as necessary)



Sheet

14

of

15

Attorney Docket No.

PHA 4298 (3167/9Z)

195.	SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10	
196.	STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- $\alpha$ , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, Journal of Clinical Oncology, May 1998, pp.1820-1825, Vol. 16, No. 5	
197.	STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, Journal of Clinical Oncology, May, 1992, pp. 829-838, Vol. 10, No. 5	
198.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages <sup>1</sup> , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58	
199.	TAKADA, Y., et al., Structures and functions of integrins, Jikken Igaku, 1996, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3	A
200.	TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, Breast Cancer Research and Treatment, 1995, pp. 227-236, Vol. 36	
201.	TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, European Journal of Cancer, 1996, pp. 2461-2466, Vol. 32A, No. 14	
202.	THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10	
203.	TOLSMA, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122	
204.	TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/868,437
		Filing Date	June 14, 2001
		Confirmation Number	Unknown
		First Named Inventor	John P. McKearn et al.
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 15 of 15	Attorney Docket No.	PHA 4298 (3167/9Z)	



RECEIVED  
 AUG 19 2003  
 TECH CENTER 1600/2200

205.	TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1	
206.	VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha v \beta 3$ , Impt. Adv. Onc., 1996, pp. 69-87	
207.	VON ROEDERN, E.G., et al., Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8), J. Med. Chem., 1998, pp. 339-345, Vol. 41	
208.	XUE, C.-B., et al., Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF- $\alpha$ Production, J. Med. Chem, 1998, pp. 1745-1748, Vol. 41	
209.	YEH, L.-A., et al., Inhibition of Metalloproteinase by Futoenone Derivatives, Bio-Organic & Medicinal Chemistry Letters, 1995, pp. 1637-1642, Vol. 5, No. 15	
210.	ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
211.	ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.